"Resistance" to PSC-RANTES revisited: Two mutations in human immunodeficiency virus type 1 HIV-1SF162 or simian-human immunodeficiency virus SHIVSF162-p3 do not confer resistance

Journal of Virology

Volumn 84, Issue 11, 2010, Pages 5842-5845

  Nedellec, Rebecca ^a   Coetzer, Mia ^a   Lederman, Michael M ^b   Offord, Robin E ^c   Hartley, Oliver ^d   Mosier, Donald E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Foundation for Medical Research   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PSC RANTES; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANIMALS; ANTI-HIV AGENTS; CHEMOKINE CCL5; DRUG RESISTANCE; HIV-1; HUMANS; MACACA; MUTATION; RECEPTORS, CCR5; RECEPTORS, VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77951996658     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01907-09     Document Type: Article

References (15)

1. Baba, M., O. Nishimura, N. Kanzaki, M. Okamoto, H. Sawada, Y. Iizawa, M. Shiraishi, Y. Aramaki, K. Okonogi, Y. Ogawa, K. Meguro, and M. Fujino. 1999. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U. S. A. 96:5698-5703.
2. Billick, E., C. Seibert, P. Pugach, T. Ketas, A. Trkola, M. J. Endres, N. J. Murgolo, E. Coates, G. R. Reyes, B. M. Baroudy, T. P. Sakmar, J. P. Moore, and S. E. Kuhmann. 2004. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J. Virol. 78:4134-4144. (Pubitemid 38437219)
3. Dudley, D. M., J. L. Wentzel, M. S. Lalonde, R. S. Veazey, and E. J. Arts. 2009. Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J. Virol. 83:5067-5076.
4. Gaertner, H., F. Cerini, J. M. Escola, G. Kuenzi, A. Melotti, R. Offord, I. Rossitto-Borlat, R. Nedellec, J. Salkowitz, G. Gorochov, D. Mosier, and O. Hartley. 2008. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. U. S. A. 105:17706-17711.
5. Hsu, M., S. H. Ho, P. Balfe, A. Gettie, J. Harouse, J. Blanchard, and C. Cheng-Mayer. 2005. A CCR5-tropic simian-HIV molecular clone capable of inducing AIDS in rhesus macaques. J. Acquir. Immune Defic. Syndr. 40:383-387.
6. Lederman, M. M., R. S. Veazey, R. Offord, D. E. Mosier, J. Dufour, M. Mefford, M. Piatak, Jr., J. D. Lifson, J. R. Salkowitz, B. Rodriguez, A. Blauvelt, and O. Hartley. 2004. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306:485-487.
7. Lobritz, M. A., A. J. Marozsan, R. M. Troyer, and E. J. Arts. 2007. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J. Virol. 81:8258-8269.
8. Marcon, L., H. Choe, K. A. Martin, M. Farzan, P. D. Ponath, L. Wu, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1997. Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J. Virol. 71:2522-2527. (Pubitemid 27078640)
9. Pastore, C., R. Nedellec, A. Ramos, S. Pontow, L. Ratner, and D. E. Mosier. 2006. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J. Virol. 80:750-758. (Pubitemid 43062887)
10. Pastore, C., G. R. Picchio, F. Galimi, R. Fish, O. Hartley, R. E. Offord, and D. E. Mosier. 2003. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob. Agents Chemother. 47:509-517.
11. Tsibris, A. M., M. Sagar, R. M. Gulick, Z. Su, M. Hughes, W. Greaves, M. Subramanian, C. Flexner, F. Giguel, K. E. Leopold, E. Coakley, and D. R. Kuritzkes. 2008. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 82:8210-8214.
12. Veazey, R. S., B. Ling, L. C. Green, E. P. Ribka, J. D. Lifson, M. Piatak, Jr., M. M. Lederman, D. Mosier, R. Offord, and O. Hartley. 2009. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J. Infect. Dis. 199:1525-1527.
13. Weiler, A., G. E. May, Y. Qi, N. Wilson, and D. I. Watkins. 2006. Polymorphisms in eight host genes associated with control of HIV replication do not mediate elite control of viral replication in SIV-infected Indian rhesus macaques. Immunogenetics 58:1003-1009. (Pubitemid 44791233)
14. Westby, M., C. Smith-Burchnell, J. Mori, M. Lewis, M. Mosley, M. Stockdale, P. Dorr, G. Ciaramella, and M. Perros. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371. (Pubitemid 46303353)
15. Whitcomb, J. M., W. Huang, S. Fransen, K. Limoli, J. Toma, T. Wrin, C. Chappey, L. D. Kiss, E. E. Paxinos, and C. J. Petropoulos. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575.